Arch Biopartners Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Arch Biopartners Inc. is a therapeutic biotechnology company headquartered in Toronto, Canada, specializing in the development of novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The company’s core products include its lead drug candidates LSALT peptide (Metablok) and cilastatin, which are designed to prevent and treat inflammation and toxin-induced kidney injuries. Arch's portfolio spans both acute and chronic kidney disease with a particular focus on innovative therapeutics targeting the dipeptidase-1 (DPEP1) inflammation pathway implicated in kidney, lung, and liver damage. It operates clinical programs including an international Phase II trial for LSALT peptide aimed at preventing AKI related to cardiac surgery and another investigator-led Phase II trial using cilastatin for drug-toxin-related AKI. Arch also advances a novel CKD platform targeting the IL-32 cytokine, significant in diabetic kidney disease, reinforcing its presence in kidney therapeutics. Founded in 2010, Arch Biopartners collaborates closely with academic and research institutions to build its robust patent portfolio and therapeutic pipeline. Recent major changes include the acquisition of a new CKD platform in 2025 with potential to produce next-generation CKD drugs, the closing of a non-brokered private placement to support ongoing trials, and the successful initiation and dosing of patients in multiple Phase II clinical trials addressing AKI. The company’s strategic focus on kidney disease therapeutics positions it as a key player in addressing significant unmet medical needs in North America and beyond.
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI
Arch Biopartners Closes Non-Brokered Private Placement
Arch Biopartners Arranges Non-Brokered Private Placement
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
Arch Biopartners Closes Non-Brokered Private Placement
Arch Biopartners Arranges Non-Brokered Private Placement
Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
Arch Biopartners Arranges Non-Brokered Private Placement
Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)
Shares for Interest Debt Settlement
Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)